



**The Clatterbridge
Cancer Centre**
NHS Foundation Trust

Clatterbridge Road
Bebington
Wirral
CH63 4JY

Tel: 0151 556 5000
Web: www.clatterbridgecc.nhs.uk

Date: 30th April 2018

Re: Freedom of Information Request
Ref: 73-2018

Thank you for your email dated 10th April 2018 in relation to research into Non-Small Cell Lung Cancer (NSCLC).

For the information requested please see Appendix 1.

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could

take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Appendix 1

FOI Request re Non-Small Cell Lung Cancer (NSCLC) Patients

Please provide the following information relating to NSCLC¹ patients treated² by your Trust in the 3 months, December 2017 to February 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Patients with NSCLC Stage IIIB/IV (Stage 3b/4) ³	127 treatments (x124 patients) <i>Staging is from 1st Presentation</i>	Total number NSCLC patients	127 treatments (x124 patients) IIIB = 32 IV = 92
		Other (please specify)	-
		Data not held/accessible	-

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months December 2017 to February 2018 inclusive, with the following therapies.

	Total number treated Stage IIIB/IV NSCLC Patients	If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:	
Docetaxel (mono or combination therapy)	9 (x6 Docetaxel X3 Docetaxel + Nintedanib) <i>Staging is from 1st Presentation</i>	Total number NSCLC patients	IIIB = 1 IV = 8
		Other (please specify)	-
		Data not held/accessible	-
Atezolizumab (Tecentriq)	0 <i>Staging is from 1st Presentation</i>	Total number NSCLC patients	0
		Other (please specify)	-
		Data not held/accessible	-
Nivolumab (Opdivo)	13 (x10 Nivolumab X3 Nivolumab + Ipilimumab) <i>Staging is from 1st Presentation</i>	Total number NSCLC patients	IIIB = 6 IV = 7
		Other (please specify)	-
		Data not held/accessible	-
Pembrolizumab (Keytruda)	105 <i>Staging is from 1st Presentation</i>	Total number NSCLC patients	IIIB = 25 IV = 80
		Other (please specify)	-
		Data not held/accessible	-

¹ ICD10 C33, C34

² Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

³ TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1

Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred: